-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abelacimab in Venous (Vein) Thrombosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abelacimab in Venous (Vein) Thrombosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abelacimab in Venous (Vein) Thrombosis Drug Details: Abelacimab is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Motixafortide Acetate in Pancreatic Ductal Adenocarcinoma Drug Details: Motixafortide is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abelacimab in Atrial Fibrillation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abelacimab in Atrial Fibrillation Drug Details: Abelacimab is under development for the prevention of venous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abelacimab in Deep Vein Thrombosis (DVT)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abelacimab in Deep Vein Thrombosis (DVT) Drug Details: Abelacimab is under development for the prevention...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abelacimab in Ischemic Stroke
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Abelacimab in Ischemic Stroke Drug Details: Abelacimab is under development for the prevention of venous...
-
Product Insights
Pulmonary Embolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Embolism - Drugs In Development, 2023’, provides an overview of the Pulmonary Embolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Atrial Fibrillation – Drugs In Development, 2023
Global Markets Direct’s, ‘Atrial Fibrillation - Drugs In Development, 2023’, provides an overview of the Atrial Fibrillation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Deep Vein Thrombosis (DVT) – Drugs In Development, 2023
Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) - Drugs In Development, 2023’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Venous (Vein) Thrombosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Venous (Vein) Thrombosis - Drugs In Development, 2023’, provides an overview of the Venous (Vein) Thrombosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venous (Vein) Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Thromboembolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Thromboembolism - Drugs In Development, 2023’, provides an overview of the Thromboembolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...